Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 31;30(Suppl 1):76-81.
doi: 10.31138/mjr.30.1.76. eCollection 2019 Jun.

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience

Wieland D Müskens  1 , Sanne A A Rongen-van Dartel  1   2 , Eddy M M Adang  3 , Piet L C M van Riel  1   2
Affiliations
Review

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience

Wieland D Müskens et al. Mediterr J Rheumatol. .

Abstract

These days, the use of biosimilars for the treatment of bio-naive patients is well established. However, the transition of patients being treated with a bio-originator to its biosimilar is still a topic of discussion. The main issue is which approach to use when initiating the non-medical transition. The first real-world examples contain both mandatory and non-mandatory approaches, resulting in a variety of acceptance and discontinuation rates. At this moment a non-mandatory approach, based on shared decision making, is preferred by international guidelines and the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. However, clear definitions of mandatory and non-mandatory are lacking, as a result of which these terms may be wrongly used in some studies. This article aims to provide an overview of transition approaches used in the Netherlands, and how the approach used relates to acceptance and discontinuation rates of the biosimilar.

Keywords: Biosimilars; biologicals; nocebo-effect; non-medical switch; switching.

PubMed Disclaimer

References

    1. The Dutch Medicines Board Opinion on Biosimilars, (2015).
    1. Standpunt Biosimilars Federatie Medisch Specialisten, (2017).
    1. Monitor geneesmiddelen in de medisch-specialistische zorg: Nederlandse Zorgautoriteit; 2017 [Available from: https://www.rijksoverheid.nl/documenten/rapporten/2017/12/21/monitor-gen...]
    1. Zorggids RN. Patent op reumamedicijn verlopen: prijs met 80 procent omlaag 2018. [Available from: https://www.nationalezorggids.nl/zorgverzekering/nieuws/45912-patent-opr...]
    1. Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019;78(2):192–200. [10.1136/annrheumdis-2018-213474] [PMID: ] - DOI - PubMed

LinkOut - more resources